HIV testing and same-day PrEP navigation in New York

HIV detection depends on the assay and exposure date. CDC lists usual windows of 10–33 days for NAT and 18–45 days for a laboratory antigen/antibody test using venous blood. Rapid finger-stick antigen/antibody testing has a usual window of 18–90 days; antibody testing has a window of 23–90 days. A negative result during its window is not conclusive; repeat at the advised time. PrEP/PEP can affect the testing plan. If the exposure was within 72 hours, seek urgent PEP assessment rather than waiting for repeat testing.

Some HIV tests can produce a rapid result, while a laboratory test or confirmation may take longer. Ask which assay the clinic uses, when your result will be discussed and what follow-up is needed. A same-day negative does not exclude a recent exposure within that assay's window. A reactive screening result needs confirmation. Seek urgent PEP assessment for a qualifying exposure within 72 hours.

Describe exposures, previous results, PrEP/PEP use and symptoms. A negative baseline test is useful but does not exclude the exposure that just occurred.

Ask whether the test is an antibody test, a laboratory venous antigen/antibody test, a finger-stick combination test or a NAT. Recent exposure or acute symptoms may call for additional tests rather than a rapid antibody test alone.

Without antiretroviral use, CDC usual detection windows are 10–33 days for NAT and 18–45 days for a venous laboratory antigen/antibody test. The windows are 18–90 days for a finger-stick combination test and 23–90 days for antibody tests. These ranges are not an individualized guarantee.

An early negative may need repeat testing. A reactive screening result needs confirmatory testing and prompt clinical contact. A confirmed positive result should connect you to HIV care; a negative result can connect you to appropriate prevention.

Your follow-up date depends on assay, exposure timing, ongoing risk and PrEP/PEP use. CDC’s post-PEP schedule differs from ordinary untreated-infection windows. If tests conflict or acute HIV is suspected, additional testing and a clinician-managed prevention plan are needed. Keep the follow-up even if you feel well; symptoms are an unreliable testing strategy.

A clinician may consider a rapid oral PrEP start after the required HIV assessment and product-specific safety review. A negative oral-fluid self-test or a booked appointment does not by itself exclude acute HIV or establish eligibility. Recent exposure within 72 hours may require PEP instead. Kidney function, hepatitis B, exposure route and the exact formulation affect the plan. Do not start borrowed pills or stop current prevention on your own.

Ask whether the service provides confidential identified testing or a specifically anonymous pathway; these are different. Insurance claims or benefit communications can reveal that a service occurred. Minors need the applicable consent and privacy process and an age-appropriate service. Tell intake your age and privacy concerns and ask who can see results. Ask for a clinician who can address your specific concerns.

Repeat testing depends on the exposure date, assay, ongoing risk and any PrEP/PEP use. An early negative may need another test after the applicable window. Oral PrEP generally includes HIV testing at least every three months. Injections use their product-specific testing visits. PEP has a separate 4–6- and 12-week follow-up plan. Ask the clinician for your next test date.

Possible HIV exposure is time-sensitive. Seek PEP assessment as soon as possible, ideally within 24 hours and no later than 72 hours after a qualifying exposure. PEP is a 28-day course of antiretroviral medication used after exposure; it is different from ongoing PrEP. Do not wait for symptoms, a partner’s results, insurance approval or a routine appointment. If a clinic cannot assess you promptly, go to an emergency department or another service able to start PEP.

Tell the service the exact date and time, what happened, any prior PrEP doses and what is known about the source. If sexual assault occurred, urgent care can also address injuries, pregnancy prevention, other infections and support; PEP decisions should not wait for reporting or paperwork.

A baseline HIV test and renal, hepatic, hepatitis, STI or pregnancy testing may be needed. When PEP is indicated, the first dose should not be delayed waiting for laboratory results that are unavailable immediately.

Confirm where the medication will be dispensed, how the full 28-day supply will be obtained and whom to call for side effects or a missed dose. The regimen is selected for age, pregnancy, organ function and interactions.

CDC recommends early contact around 24 hours to check access and tolerance, with clinical/laboratory follow-up at 4–6 and 12 weeks after exposure. Your clinician specifies the HIV antigen/antibody and nucleic-acid tests and any timing adjustments.

It depends on the test and clinical context. Many tests are still within their detection window at two weeks. Tell the clinician about exposure timing and PrEP/PEP so the right test and repeat date can be selected.

“Nonreactive” means the screening test did not detect the HIV marker it measures in that sample. It is usually reported as a negative result, but it can be too early after exposure to exclude infection. Interpretation depends on the assay, specimen, exposure date and any PrEP or PEP. Ask whether you need another test after the applicable window or additional testing for possible acute HIV. A potential qualifying exposure within 72 hours needs urgent PEP assessment. Your result does not establish your partner’s HIV status.

Ask a clinician or a sexual-health testing service which HIV assay it provides and how follow-up is arranged. CDC’s testing locator and NYC Health Department sexual-health clinics are published ways to find services. Confirm current location requirements before going. Tell the service your exposure date, symptoms and PrEP/PEP use so the test fits the question. A blood or oral-fluid test detects HIV, while an AIDS diagnosis involves the stage of established HIV disease and clinical assessment. A reactive screen needs confirmation. A qualifying exposure within 72 hours calls for urgent PEP care rather than waiting for a testing appointment.

Antibody tests look for the immune response to HIV. Antigen/antibody tests also detect p24 antigen. A nucleic-acid test, or NAT, looks for viral genetic material. The tests become positive at different times after infection. Viral-load testing in someone with diagnosed HIV serves a different purpose from screening and must not be confused with a general negative HIV test.